Adam L Halberstadt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/46282/publications.pdf

Version: 2024-02-01

69 papers	3,965 citations	117453 34 h-index	128067 60 g-index
70 all docs	70 docs citations	70 times ranked	2986 citing authors

#	Article	IF	Citations
1	(2-Aminopropyl)benzo[Î²]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice. Neuropsychopharmacology, 2022, 47, 914-923.	2.8	8
2	Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1â€valeroylâ€<scp>d</scp>â€lysergic acid diethylamide (1Vâ€LSD). Drug Testing and Analysis, 2022, 14, 733-740.	1.6	8
3	Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1Pâ€ALâ€LAD. Drug Testing and Analysis, 2022, 14, 1503-1518.	1.6	7
4	Investigation of the Structureâ€“Activity Relationships of Psilocybin Analogues. ACS Pharmacology and Translational Science, 2021, 4, 533-542.	2.5	58
5	Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity. Journal of Natural Products, 2021, 84, 1403-1408.	1.5	7
6	HIV Transgenic Rats Demonstrate Impaired Sensorimotor Gating But Are Insensitive to Cannabinoid (Î”9-Tetrahydrocannabinol)-Induced Deficits. International Journal of Neuropsychopharmacology, 2021, 24, 894-906.	1.0	6
7	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews, 2021, 73, 310-520.	7.1	127
8	Response to Mukhdomi and Mukhdomiâ€™s letter to the editor. Regional Anesthesia and Pain Medicine, 2021, 46, 557-558.	1.1	0
9	Convergent neural substrates of inattention in bipolar disorder patients and dopamine transporterâ€deficient mice using the 5â€choice CPT. Bipolar Disorders, 2020, 22, 46-58.	1.1	21
10	Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology, 2020, 167, 107933.	2.0	132
11	Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD). Neuropharmacology, 2020, 172, 107856.	2.0	22
12	Acute serotonin 2A receptor activation impairs behavioral flexibility in mice. Behavioural Brain Research, 2020, 395, 112861.	1.2	18
13	Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison. Schizophrenia Bulletin, 2020, 46, 1396-1408.	2.3	55
14	Analytical profile of N â€ethylâ€•N â€cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4â€dimethylazetidide (LSZ). Drug Testing and Analysis, 2020, 12, 1514-1521.	1.6	4
15	Syntheses and analytical characterizations of novel (2â€aminopropyl)benzo[b]thiophene (APBT) based stimulants. Drug Testing and Analysis, 2020, 12, 1109-1125.	1.6	2
16	Chronic pain and psychedelics: a review and proposed mechanism of action. Regional Anesthesia and Pain Medicine, 2020, 45, 486-494.	1.1	62
17	Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network. Scientific Reports, 2020, 10, 8344.	1.6	27
18	Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1â€cyclopropanoylâ€dâ€lysergic acid diethylamide (1CPâ€LSD). Drug Testing and Analysis, 2020, 12, 812-826.	1.6	17

#	Article	IF	Citations
19	Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists. ACS Chemical Neuroscience, 2020, 11, 1238-1244.	1.7	11
20	Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin. Journal of Natural Products, 2020, 83, 461-467.	1.5	47
21	The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH. Biochemical Pharmacology, 2020, 177, 113979.	2.0	15
22	Pharmacological characterizations of the 'legal high' fluorolintane and isomers. European Journal of Pharmacology, 2019, 857, 172427.	1.7	1
23	Return of the lysergamides. Part V: Analytical and behavioural characterization of 1â€butanoylâ€dâ€lysergic acid diethylamide (1Bâ€LSD). Drug Testing and Analysis, 2019, 11, 1122-1133.	1.6	43
24	2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and Î±2-adrenergic receptors. Psychopharmacology, 2019, 236, 989-999.	1.5	3
25	Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice. Journal of Psychopharmacology, 2019, 33, 406-414.	2.0	18
26	Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen. Psychopharmacology, 2019, 236, 821-830.	1.5	19
27	Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran (â€œFLYâ€) and benzodifuran (â€œDragonFLYâ€) analogs. Neuropharmacology, 2019, 144, 368-376.	2.0	20
28	Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 2019, 236, 799-808.	1.5	21
29	Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs. Neuropharmacology, 2018, 142, 231-239.	2.0	31
30	Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSMâ€775). Drug Testing and Analysis, 2018, 10, 310-322.	1.6	40
31	Analytical characterization of N,Nâ€diallyltryptamine (DALT) and 16 ringâ€substituted derivatives. Drug Testing and Analysis, 2017, 9, 115-126.	1.6	8
32	Return of the lysergamides. Part II: Analytical and behavioural characterization of N⁶â€allylâ€6â€norlysergic acid diethylamide (ALâ€LAD) and (2â€™S,4â€™S)â€lysergic acid 2,4â€dimethylazetidide (LSZ). Drug Testing and Analysis, 2017, 9, 38-50.	1.6	51
33	Pharmacology and Toxicology of N-Benzylphenethylamine (â€œNBOMeâ€) Hallucinogens. Current Topics in Behavioral Neurosciences, 2017, 32, 283-311.	0.8	76
34	Hallucinogenic Drugs: A New Study Answers Old Questions about LSD. Current Biology, 2017, 27, R156-R158.	1.8	7
35	Return of the lysergamides. Part III: Analytical characterization of N⁶â€ethylâ€6â€norlysergic acid diethylamide (ETHâ€LAD) and 1â€propionyl ETHâ€LAD (1Pâ€“ETHâ€LAD). Drug Testing and Analysis, 2017, 9, 1641-1649.	1.6	33
36	Pharmacological Investigations of the Dissociative â€˜Legal Highsâ€™ Diphenidine, Methoxphenidine and Analogues. PLoS ONE, 2016, 11, e0157021.	1.1	55

#	Article	IF	Citations
37	Effect of Hallucinogens on Unconditioned Behavior. Current Topics in Behavioral Neurosciences, 2016, 36, 159-199.	0.8	63
38	Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice. Neuropharmacology, 2016, 107, 364-375.	2.0	34
39	Effects of the psychotomimetic benzomorphan N -allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice. Pharmacology Biochemistry and Behavior, 2016, 148, 69-75.	1.3	4
40	Premature responses in the five-choice serial reaction time task reflect rodentsâ€™ temporal strategies: evidence from no-light and pharmacological challenges. Psychopharmacology, 2016, 233, 3513-3525.	1.5	45
41	Return of the lysergamides. Part I: Analytical and behavioural characterization of 1â€propionylâ€dâ€lysergic acid diethylamide (1Pâ€LSD). Drug Testing and Analysis, 2016, 8, 891-902.	1.6	64
42	Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine. Pharmacology Biochemistry and Behavior, 2016, 143, 1-10.	1.3	23
43	The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents. Psychopharmacology, 2016, 233, 1215-1225.	1.5	35
44	BDNF-Deficient Mice Show Reduced Psychosis-Related Behaviors Following Chronic Methamphetamine. International Journal of Neuropsychopharmacology, 2016, 19, pyv116.	1.0	37
45	N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT₂ Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues. ACS Chemical Neuroscience, 2015, 6, 1165-1175.	1.7	69
46	Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 2015, 277, 99-120.	1.2	221
47	PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program. Journal of Psychoactive Drugs, 2014, 46, 73-77.	1.0	103
48	Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology, 2014, 77, 200-207.	2.0	95
49	Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. Journal of Affective Disorders, 2014, 155, 247-254.	2.0	41
50	Characterization of the head-twitch response induced by hallucinogens in mice. Psychopharmacology, 2013, 227, 727-739.	1.5	139
51	Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice. Neuropharmacology, 2013, 70, 218-227.	2.0	42
52	A novel visuospatial priming task for rats with relevance to Tourette syndrome and modulation of dopamine levels. Neuroscience and Biobehavioral Reviews, 2013, 37, 1139-1149.	2.9	21
53	Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses. Frontiers in Pharmacology, 2013, 4, 109.	1.6	7
54	Serotonergic hallucinogens as translational models relevant to schizophrenia. International Journal of Neuropsychopharmacology, 2013, 16, 2165-2180.	1.0	51

#	Article	IF	Citations
55	Four factors underlying mouse behavior in an open field. Behavioural Brain Research, 2012, 233, 55-61.	1.2	77
56	Behavioral effects of Î±,Î±,Î²,Î²-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology, 2012, 221, 709-718.	1.5	33
57	Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats. Pharmacology Biochemistry and Behavior, 2012, 102, 88-94.	1.3	4
58	Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. Journal of Psychopharmacology, 2011, 25, 1548-1561.	2.0	135
59	Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 2011, 61, 364-381.	2.0	274
60	Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT1A receptor knockout mice: Implications for schizophrenia. Neuropharmacology, 2011, 61, 209-216.	2.0	39
61	Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice. Psychopharmacology, 2011, 215, 81-92.	1.5	28
62	Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Archives of General Psychiatry, 2011, 68, 71.	13.8	806
63	LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor. Psychopharmacology, 2010, 208, 179-189.	1.5	62
64	5-HT2A and 5-HT2C Receptors Exert Opposing Effects on Locomotor Activity in Mice. Neuropsychopharmacology, 2009, 34, 1958-1967.	2.8	127
65	Habituation and sensitization of acoustic startle: Opposite influences of dopamine D1 and D2-family receptors. Neurobiology of Learning and Memory, 2009, 92, 243-248.	1.0	36
66	Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology, 2008, 201, 55-66.	1.5	42
67	Projections from the vestibular nuclei and nucleus prepositus hypoglossi to dorsal raphe nucleus in rats. Neuroscience Letters, 2008, 439, 70-74.	1.0	15
68	Selective anterograde tracing of nonserotonergic projections from dorsal raphe nucleus to the basal forebrain and extended amygdala. Journal of Chemical Neuroanatomy, 2008, 35, 317-325.	1.0	18
69	The Phencyclidine-Glutamate Model of Schizophrenia. Clinical Neuropharmacology, 1995, 18, 237-249.	0.2	95